FibroGen, Inc. (Nasdaq: FGEN) — Form 10-Q summary
Filing identity: The filing names FibroGen, Inc., not KYNTRA BIO, INC. It covers the quarter and nine months ended September 30, 2019; financial statements are unaudited. Amounts below are in U.S. dollars unless noted.
Business context and reporting period
FibroGen is a biopharmaceutical company developing roxadustat for anemia and pamrevlumab for fibrotic disease and cancer. Roxadustat was approved in China for CKD anemia in dialysis and non-dialysis patients and in Japan for dialysis patients. Pamrevlumab was in Phase 3 trials for idiopathic pulmonary fibrosis and pancreatic cancer, and Phase 2 for Duchenne muscular dystrophy. FibroGen began commercial roxadustat sales in China during the quarter.
Financial performance and liquidity
| Metric | Three months ended Sept. 30, 2019 | Three months ended Sept. 30, 2018 | Nine months ended Sept. 30, 2019 | Nine months ended Sept. 30, 2018 |
|---|---|---|---|---|
| Revenue | $33.2 million | $29.0 million | $248.6 million | $104.9 million |
| Operating costs and expenses | $86.0 million | $71.8 million | $237.5 million | $211.5 million |
| Operating income (loss) | $(52.9) million | $(42.8) million | $11.1 million | $(106.6) million |
| Net income (loss) | $(49.4) million | $(42.6) million | $21.2 million | $(107.4) million |
| Basic earnings (loss) per share | $(0.57) | $(0.50) | $0.24 | $(1.28) |
| Cash used in operating activities | Not provided for the quarter | $33.7 million | $58.7 million |
- At September 30, 2019, cash and cash equivalents were $196.6 million; short- and long-term investments totaled $443.0 million. Together these were approximately $639.6 million. Management also cited $658.9 million in cash, cash equivalents, investments and accounts receivable.
- Total assets were $894.0 million and total liabilities were $280.2 million. The filing reports lease liabilities of about $55.0 million, product-development obligations of $16.3 million, and no conventional borrowing balance identified in the provided text.
- Current assets were $786.5 million versus current liabilities of $87.3 million. The company said its financial resources were expected to cover anticipated cash needs for at least 12 months from the filing date.
- Product revenue was $0.6 million and cost of goods sold was $0.2 million in the quarter, reflecting the initial China launch. Product sales remained small relative to collaboration revenue.
Material changes versus prior comparable periods
- Quarterly revenue rose 14%, while the net loss widened from $42.6 million to $49.4 million. Quarterly SG&A increased 133%, primarily due to commercial preparation and outside services; R&D declined 11%, largely reflecting lower roxadustat trial activity and reduced pamrevlumab manufacturing costs.
- Nine-month revenue more than doubled, and results shifted from a $107.4 million net loss to $21.2 million net income. This improvement was substantially driven by collaboration milestone accounting, rather than significant product sales.
- Revenue included recognition associated with a $12.5 million Japan approval milestone, $130.0 million in Europe regulatory milestones that became probable in Q2, and a $50.0 million U.S. regulatory milestone that became probable in Q2. The latter two milestone amounts were not yet billable pending the planned MAA and NDA submissions; associated contract assets affected working capital and cash flow.
- Cash and cash equivalents increased from $89.3 million at year-end 2018, while investments declined from $588.0 million to $443.0 million. Operating cash use improved year over year, but remained negative.
Outlook, commentary and risks
- Management expected to submit the roxadustat U.S. NDA in Q4 2019 and the European MAA in Q1 2020. These were expectations as of the filing, not completed submissions.
- Management expected continued losses and substantial spending on development, regulatory work and commercialization; it also said additional funding might be needed. The company was highly dependent on AstraZeneca and Astellas for roxadustat development and commercialization.
- Clinical data reported by the company showed efficacy in Phase 3 CKD studies and pooled cardiovascular safety results it considered supportive. The FDA and EMA would perform their own benefit-risk reviews, and the filing notes that further analysis, different regulatory interpretations, additional trials or safety findings could delay or prevent approval. Reported trial adverse events included hypertension, nausea, hyperkalemia and other events; risks vary by study and patient population.
- Roxadustat commercialization in China faced uncertainty around reimbursement, pricing, hospital access, competition, manufacturing and distribution. The company also disclosed ongoing patent challenges and proceedings involving certain European patents.
- Founder, chairman and CEO Thomas B. Neff died in August 2019. James Schoeneck was appointed interim CEO while the board searched for a permanent CEO. Management cited leadership transition as a potential operational risk.
- FibroGen adopted ASC 842 lease accounting in 2019, recognizing right-of-use assets and lease liabilities and recording an $8.7 million cumulative adjustment to opening retained earnings. The filing says adoption did not materially affect the period’s statements of operations or cash flows.
Most important facts for investors to verify
- Confirm the filing entity: this 10-Q is for FibroGen, Inc. (FGEN), which conflicts with the request metadata naming KYNTRA BIO, INC.
- Track actual timing and regulatory outcomes for the anticipated U.S. NDA and European MAA, and the FDA/EMA review of roxadustat’s efficacy and cardiovascular safety data.
- Separate recurring collaboration and product revenue from milestone-related revenue; verify when the $180 million in planned-submission milestones becomes billable and collected.
- Monitor operating cash burn, investment liquidity, China launch economics and whether management’s stated 12-month funding estimate remains valid.
- Assess pamrevlumab trial progress, roxadustat safety and post-approval obligations, partner commitment, China reimbursement and commercial execution, and the effects of the CEO transition and patent proceedings.